Pegasus Biotech, a full-service biotechnology contract research organization, has announced the successful redesign of plasmid DNA replication. This new technology enables precise control over when and how DNA is produced, resulting in significantly higher replication levels compared to existing technology. The BPE plasmid technology utilizes a patented origin that can lay dormant during fermentation and trigger replication at high cell densities.
One of the key advantages of this technology is that it does not use an antibiotic resistance selection marker and contains minimal bacterial sequences, less than 1,000 base pairs. This makes it ideal for applications where cost of goods sold and patient safety are important factors.
In addition to its improved replication capabilities, the BPE plasmid technology also offers enhanced expression. Cells transfected with this plasmid show up to 7 times more expression than conventional plasmid backbones. Daniel Wilson, COO of Pegasus Biotech, emphasized the transformational nature of this technology in applications where high expression levels are critical.
Pegasus Biotech specializes in ensuring that client projects comply with global regulations and result in commercially viable products. Their services include seed-to-formulation process development and associated analytical development. For more information on Pegasus’ services, visit their website.
The company aims to facilitate the development and market entry of innovative biopharmaceutical and vaccine products. With its expertise in vaccine and biopharmaceutical development, Pegasus Biotech is a global leader in DNA vaccine development. For media inquiries, please contact Daniel Wilson at Pegasus Biotech Inc., via email or visit www.pegasusbio.com. Source: Pegasus Biotech Inc